Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Supportive care

Approved-not yet active

18 and over

Pharmaceutical / Industry

A4091003
NCT00545129

Trial Description

Summary

The purpose of this study is to investigate the safety and efficacy of tanezumab in comination with opioids in treating pain due to cancer that has spread to bone.

Eligibility Criteria

Inclusion Criteria:

Prostate cancer or breast cancer that has spread to bone, causing moderate to severe bone pain.

Requires daily opioid medication

Exclusion Criteria:

Patients who do not have bone pain caused by cancer are not eligible for the study.

Patients who started chemotherapy less than 4 weeks ago, or who completed radiotherapy less than 4 weeks ago, are not eligible.

Trial Contact Information

Trial Lead Organizations/Sponsors

Pfizer Incorporated

Pfizer CT.gov Call Center

Study Director

Pfizer CT.gov Call Center

Ph: 1-800-718-1021

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00545129
Information obtained from ClinicalTrials.gov on October 16, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.